NCT07864623 · NOT YET RECRUITING
A Postmarketing Study of LEQEMBI in Participants With Alzheimer's Disease
This postmarketing study looks at how well LEQEMBI (lecanemab), an anti-amyloid antibody already approved in Canada, slowed changes in thinking and daily function over 18 months. It uses a score called CDR-SB and compares results with placebo participants from an earlier study. No phase is listed. Details are limited so far.
You may qualify if
- Participant (or legally authorized representative) has provided written informed consent to participate in the local site registry
- Mild cognitive impairment (MCI) due to AD or mild AD dementia, according to the National Institute on Aging - Alzheimer's Association (NIA-AA) criteria
- Global CDR at baseline of 0.5 or 1
- APOE4 heterozygous or noncarrier
- Have had a baseline CDR-SB (before initiation of LEQEMBI treatment)
- Completed 18 months of LEQEMBI treatment, with an 18-month CDR-SB assessment
You're excluded if
- Use of any other anti-amyloid treatment prior to and during the 18-month LEQEMBI treatment period
- Conditions highlighted under "Contraindications" section in the Canadian Product Monograph
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-10-08